MedWatch

Sales of Chemometec's top products still faltering - new CEO urges patience

Chemometec has only managed to sell four of its xcyto analysis instruments, even though they have been on the market for several years. The company's new CEO is unconcerned.

Steen Søndergaard started as CEO of Chemometec on January 1. Photo: Chemometec / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles